Literature DB >> 23928869

Preprocedural TIMI flow and infarct size in STEMI undergoing primary angioplasty.

Giuseppe De Luca1, Guido Parodi, Roberto Sciagrà, Francesco Venditti, Benedetta Bellandi, Ruben Vergara, Angela Migliorini, Renato Valenti, David Antoniucci.   

Abstract

Despite optimal epicardial recanalization, primary angioplasty for STEMI is still associated with suboptimal reperfusion in a relatively large proportion of patients. The aim the current study was to evaluate the impact of preprocedural TIMI flow on myocardial scintigraphic infarct size among STEMI undergoing primary angioplasty. Our population is represented by 793 STEMI patients undergoing primary PCI. Infarct size was evaluated at 30 days by technetium-99m-sestamibi. Poor preprocedural TIMI flow (TIMI 0-1) was observed in 645 patients (81.3%). Poor preprocedural TIMI flow was associated with more hypercholesterolemia (p = 0.012), and a trend in lower prevalence of diabetes (p = 0.081). Preprocedural TIMI flow significantly affected scintigraphic and enzymatic infarct size. Similar findings were observed in the analysis restricted to patients with postprocedural TIMI 3 flow. The impact of preprocedural TIMI flow on scintigraphic infarct size was confirmed when the analysis was performed according to the percentage of patients above the median (p < 0.001) and after adjustment for baseline confounding factors (Hypercholesterolemia and diabetes) [adjusted OR (95% CI) for pre preprocedural TIMI 3 flow = 0.59 (0.46-0.75), p < 0.001]. This study shows that among patients with STEMI undergoing primary angioplasty, poor preprocedural TIMI flow is independently associated with larger infarct size.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 23928869     DOI: 10.1007/s11239-013-0977-x

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  36 in total

1.  Impact of preprocedural TIMI flow on myocardial perfusion, distal embolization and mortality in patients with ST-segment elevation myocardial infarction treated by primary angioplasty and glycoprotein IIb/IIIa inhibitors.

Authors:  Mauro Maioli; Uwe Zeymer; Arnoud W J van 't Hof; C Michael Gibson; Dariusz Dudek; Francesco Bellandi; Marko Noc; Gioel Gabrio Secco; Simona Zorman; H Mesquita Gabriel; Ayse Emre; Donald Cutlip; Tomasz Rakowski; Maryann Gyongyosi; Kurt Huber; Giuseppe De Luca
Journal:  J Invasive Cardiol       Date:  2012-07       Impact factor: 2.022

Review 2.  Transferring patients with ST-segment elevation myocardial infarction for mechanical reperfusion: a meta-regression analysis of randomized trials.

Authors:  Giuseppe De Luca; Giuseppe Biondi-Zoccai; Paolo Marino
Journal:  Ann Emerg Med       Date:  2008-12       Impact factor: 5.721

3.  Preprocedural Thrombolysis in Myocardial Infarction (TIMI) flow significantly affects the extent of ST-segment resolution and myocardial blush in patients with acute anterior myocardial infarction treated by primary angioplasty.

Authors:  Giuseppe De Luca; Nicolette Ernst; Arnoud W J van 't Hof; Jan Paul Ottervanger; Jan C A Hoorntje; Jan-Henk E Dambrink; A T Marcel Gosslink; Menko-Jan de Boer; Harry Suryapranata
Journal:  Am Heart J       Date:  2005-10       Impact factor: 4.749

4.  Unsuccessful reperfusion in patients with ST-segment elevation myocardial infarction treated by primary angioplasty.

Authors:  Giuseppe De Luca; Arnoud W J van 't Hof; Jan Paul Ottervanger; Jan C A Hoorntje; A T Marcel Gosselink; Jan-Henk E Dambrink; Felix Zijlstra; Menko-Jan de Boer; Harry Suryapranata
Journal:  Am Heart J       Date:  2005-09       Impact factor: 4.749

5.  Patency of infarct related artery after pharmacological reperfusion during transfer to primary percutaneous coronary intervention influences left ventricular function and one-year clinical outcome.

Authors:  Dariusz Dudek; Tomasz Rakowski; Nader El Massri; Danuta Sorysz; Jaroslaw Zalewski; Jacek Legutko; Artur Dziewierz; Lukasz Rzeszutko; Krzysztof Zmudka; Wieslawa Piwowarska; Giuseppe De Luca; Grzegorz L Kaluza; Marianna Janion; Jacek S Dubiel
Journal:  Int J Cardiol       Date:  2007-04-12       Impact factor: 4.164

6.  In vitro validation of a simple tomographic technique for estimation of percentage myocardium at risk using methoxyisobutyl isonitrile technetium 99m (sestamibi).

Authors:  M K O'Connor; T Hammell; R J Gibbons
Journal:  Eur J Nucl Med       Date:  1990

7.  Relationship between residual blood flow in the infarct-related artery and scintigraphic infarct size, myocardial salvage, and functional recovery in patients with acute myocardial infarction.

Authors:  Gjin Ndrepepa; Adnan Kastrati; Markus Schwaiger; Julinda Mehilli; Christina Markwardt; Alban Dibra; Josef Dirschinger; Albert Schömig
Journal:  J Nucl Med       Date:  2005-11       Impact factor: 10.057

8.  In-hospital time to treatment of patients with acute ST elevation myocardial infarction treated with primary angioplasty: determinants and outcome. Results from the registry of percutaneous coronary interventions in acute myocardial infarction of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausarzte.

Authors:  R Zahn; A Vogt; U Zeymer; A K Gitt; K Seidl; M Gottwik; M A Weber; W Niederer; B Mödl; H-J Engel; U Tebbe; J Senges
Journal:  Heart       Date:  2005-08       Impact factor: 5.994

Review 9.  Reperfusion in acute myocardial infarction: effect of timing and modulating factors in experimental models.

Authors:  K A Reimer; R S Vander Heide; V J Richard
Journal:  Am J Cardiol       Date:  1993-12-16       Impact factor: 2.778

10.  Impact of regional ventricular function, geometry, and dobutamine stress on quantitative 99mTc-sestamibi defect size.

Authors:  A J Sinusas; Q Shi; P J Vitols; R C Fetterman; P Maniawski; B L Zaret; F J Wackers
Journal:  Circulation       Date:  1993-11       Impact factor: 29.690

View more
  4 in total

1.  The contemporary value of peak creatine kinase-MB after ST-segment elevation myocardial infarction above other clinical and angiographic characteristics in predicting infarct size, left ventricular ejection fraction, and mortality.

Authors:  Minke H T Hartman; Ruben N Eppinga; Pieter J J Vlaar; Chris P H Lexis; Erik Lipsic; Joost D E Haeck; Dirk J van Veldhuisen; Iwan C C van der Horst; Pim van der Harst
Journal:  Clin Cardiol       Date:  2016-12-27       Impact factor: 2.882

Review 2.  Pathophysiology and Advanced Hemodynamic Assessment of Cardiogenic Shock.

Authors:  Michael I Brener; Hannah R Rosenblum; Daniel Burkhoff
Journal:  Methodist Debakey Cardiovasc J       Date:  2020 Jan-Mar

3.  Cardiovascular magnetic resonance characteristics and clinical outcomes of patients with ST-elevation myocardial infarction and no standard modifiable risk factors-A DANAMI-3 substudy.

Authors:  Jawad Mazhar; Kathrine Ekström; Rebecca Kozor; Stuart M Grieve; Lars Nepper-Christensen; Kiril A Ahtarovski; Henning Kelbæk; Dan E Høfsten; Lars Køber; Niels Vejlstrup; Stephen T Vernon; Thomas Engstrøm; Jacob Lønborg; Gemma A Figtree
Journal:  Front Cardiovasc Med       Date:  2022-08-03

4.  The effectiveness of antioxidant vitamins C and E in reducing myocardial infarct size in patients subjected to percutaneous coronary angioplasty (PREVEC Trial): study protocol for a pilot randomized double-blind controlled trial.

Authors:  Ramón Rodrigo; Daniel Hasson; Juan C Prieto; Gastón Dussaillant; Cristóbal Ramos; Lucio León; Javier Gárate; Nicolás Valls; Juan G Gormaz
Journal:  Trials       Date:  2014-05-29       Impact factor: 2.279

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.